VHL loss enables immune checkpoint blockade therapy by boosting type I interferon response.
Jiao, M.; Bao, X.; Hu, M.; Pan, D.; Liu, X.; Kim, J.; Li, F.; Li, C.-Y.
Show abstract
Despite a moderate mutation burden, clear cell renal cell carcinoma (ccRCC) responds well to immune checkpoint blockade (ICB) therapy. Here we report that loss-of-function mutations in the von Hippel-Lindau (VHL) gene, the most frequent in ccRCC, underlies its responsiveness to ICB therapy. We demonstrate that genetic knockout of the VHL gene enhanced the efficacy of anti-PD-1 therapy in multiple murine tumor models in a T cell-dependent manner. Mechanistically, we discovered that upregulation of HIF1 and HIF2 induced by VHL gene loss decreased mitochondrial outer membrane potential and caused the cytoplasmic leakage of mitochondrial DNA (mtDNA), which triggered cGAS-STING activation and induced type I interferons. Our study thus provided novel mechanistic insights into the role of VHL gene loss in potentiating ccRCC immunotherapy.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer. 97%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 97%
- Targeting PRMT3 Impairs Methylation and Oligomerization of HSP60 to Boost Anti-Tumor Immunity by Activating cGAS/STING Signaling 96%
Similar papers in this journal
- Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer 96%
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 96%
- ORMDL3 restrains type-I interferon signaling and anti-tumor immunity by promoting RIG-I degradation 96%
Similar papers in this journal
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Epigenomic signatures as circulating and predictive biomarkers in sarcomatoid renal cell carcinoma 96%
Similar papers in this journal
- SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors 96%
- Cancer cell CCR2 orchestrates suppression of the adaptive immune response 95%
- Breast cancer progression and metastasis to lymph nodes reveals cancer cell plasticity and MHC class II-mediated immune regulation 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.